Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure.
Pooled data from trials comparing nesiritide with dobutamine for treatment of acute decompensated congestive heart failure were combined with national hospital cost data in an economic model. Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs.